Study Programmes 2015-2016
Advanced Master in Industrial Pharmacy
| Block view of the study programme | Or | Th | Pr | Ot | Cr | |||||||||||||||
| Information | ||||||||||||||||||||
| Professor Ph. HUBERT Analytical Chemistry Laboratory Building B36 - CHU - 4000 Liège Phone : 04/366.43.16 - Fax : 04/366.43.17 e-mail address : Ph.Hubert@ulg.ac.be |
||||||||||||||||||||
| Collegiality | ||||||||||||||||||||
| Coordinator : Philippe HUBERT ULg : Vincent BIERLAIRE, Bruno BOULANGER, Raphaël DENOOZ, Dominique MARTIN, Laurence DENIS, Brigitte EVRARD, Marianne FILLET, Bernard PIROTTE, Eric ROZET, André SCHEEN, Monique TITS, Jean-Michel VANDERHOFSTADT, Eric ZIEMONS. ULB : Karim AMIGHI, Sonja BEKEN, Daniel BRASSEUR, Jean-Antoine DE MUYLDER, Patrick DI STEFANO, Pierre DUEZ, François DUFRASNES, Véronique FONTAINE, Ghanem GHANEM, Jean-Michel KAUFFMAN, A. LENAERS, Pierre VAN ANTWERPEN, Francis VANDERBIST, David VERMIJLEN. Pour l'UCL : Catherine DRUEZ, Bernadette GOVAERTS, Philippe LEVEQUE, Xavier MARCELIS, Jacques POUPAERT, Joëlle QUETIN-LECLERCQ, Nevin SERBEST, Jean SCOUVART, Rita VAN BEVER, Roger VERBEECK, N... |
||||||||||||||||||||
| Study programme | ||||||||||||||||||||
| Bloc 1 du programme de l'année | ||||||||||||||||||||
| Compulsory courses | ||||||||||||||||||||
| Active substances | Q1 | 6 | ||||||||||||||||||
| Active substances | ||||||||||||||||||||
| - | Substances issues de recherches pharmacochimiques, part a - Bernard Pirotte | 10 | - | - | ||||||||||||||||
| Substances issues de recherches pharmacochimiques, part a - Bernard Pirotte | ||||||||||||||||||||
| - | Substances issues de recherches pharmacochimiques, part b - Françoise Dufrasne | 5 | - | - | ||||||||||||||||
| Substances issues de recherches pharmacochimiques, part b - Françoise Dufrasne | ||||||||||||||||||||
| - | Substances issues des biotechnologies - David Vermijlen | 15 | - | - | ||||||||||||||||
| Substances issues des biotechnologies - David Vermijlen | ||||||||||||||||||||
| - | Substances d'origine naturelle, part a - Joëlle Quetin-Leclercq | 5 | - | - | ||||||||||||||||
| Substances d'origine naturelle, part a - Joëlle Quetin-Leclercq | ||||||||||||||||||||
| - | Substances d'origine naturelle, part b - Pierre Duez | 5 | - | - | ||||||||||||||||
| Substances d'origine naturelle, part b - Pierre Duez | ||||||||||||||||||||
| - | Produits radiopharmaceutiques - Ghanem Ghanem | 10 | - | - | ||||||||||||||||
| Produits radiopharmaceutiques - Ghanem Ghanem | ||||||||||||||||||||
| Clinical viewpoints | 6 | |||||||||||||||||||
| Clinical viewpoints | ||||||||||||||||||||
| - | Métabolisme des médicaments et paramètres pharmacocinétiques - Roger Verbeek | 20 | - | - | ||||||||||||||||
| Métabolisme des médicaments et paramètres pharmacocinétiques - Roger Verbeek | ||||||||||||||||||||
| - | Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - Régis Radermecker | 15 | - | - | ||||||||||||||||
| Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - Régis Radermecker | ||||||||||||||||||||
| - | Information et pharmacovigilance - Raphaël Denooz | 10 | - | - | ||||||||||||||||
| Information et pharmacovigilance - Raphaël Denooz | ||||||||||||||||||||
| Quality assurance and pharmaceutical management | 7 | |||||||||||||||||||
| Quality assurance and pharmaceutical management | ||||||||||||||||||||
| - | Principles of pharmaceutical management - Jean-Michel Van Der Hofstadt | 10 | - | - | ||||||||||||||||
| Principles of pharmaceutical management - Jean-Michel Van Der Hofstadt | ||||||||||||||||||||
| - | Quality assurance, part a : basic concepts and quality assurance organisation - Jean Scouvart | 20 | - | - | ||||||||||||||||
| Quality assurance, part a : basic concepts and quality assurance organisation - Jean Scouvart | ||||||||||||||||||||
| - | Quality assurance, part b : Analytical technology of procedures and risk analysis - Xavier Marcelis | 7,5 | - | - | ||||||||||||||||
| Quality assurance, part b : Analytical technology of procedures and risk analysis - Xavier Marcelis | ||||||||||||||||||||
| - | English applied to the pharmaceutical industry - Jacques Poupaert, Nevin Serbest | 20 | - | - | ||||||||||||||||
| English applied to the pharmaceutical industry - Jacques Poupaert, Nevin Serbest | ||||||||||||||||||||
| - | Pharmaceutical marketing - Vincent Bierlaire | 7,5 | - | - | ||||||||||||||||
| Pharmaceutical marketing - Vincent Bierlaire | ||||||||||||||||||||
| Industrial pharmaceutical technology | 8 | |||||||||||||||||||
| Industrial pharmaceutical technology | ||||||||||||||||||||
| - | Industrial pharmaceutical microbiology - Véronique Fontaine | 15 | - | - | ||||||||||||||||
| Industrial pharmaceutical microbiology - Véronique Fontaine | ||||||||||||||||||||
| - | Preformulation and selection of galenical forms - Karim Amighi | 15 | - | - | ||||||||||||||||
| Preformulation and selection of galenical forms - Karim Amighi | ||||||||||||||||||||
| - | Industrial production of galenical forms - Brigitte Evrard | 15 | - | - | ||||||||||||||||
| Industrial production of galenical forms - Brigitte Evrard | ||||||||||||||||||||
| - | Industrial production of biomolecules - Philippe Leveque, Rita Van Bever | 15 | - | - | ||||||||||||||||
| Industrial production of biomolecules - Philippe Leveque, Rita Van Bever | ||||||||||||||||||||
| - | Industrial aspects of technological development including packaging - Laurence Denis | 10 | - | - | ||||||||||||||||
| Industrial aspects of technological development including packaging - Laurence Denis | ||||||||||||||||||||
| Drug analysis | 7 | |||||||||||||||||||
| Drug analysis | ||||||||||||||||||||
| - | Analytical methods and pharmaceutical and biopharmaceutical control, part a - Jean-Michel Kauffman, Pierre Van Antwerpen | 10 | - | - | ||||||||||||||||
| Analytical methods and pharmaceutical and biopharmaceutical control, part a - Jean-Michel Kauffman, Pierre Van Antwerpen | ||||||||||||||||||||
| - | Analytical methods and pharmaceutical and biopharmaceutical control, part b - Marianne Fillet | 10 | - | - | ||||||||||||||||
| Analytical methods and pharmaceutical and biopharmaceutical control, part b - Marianne Fillet | ||||||||||||||||||||
| - | Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment - Philippe Hubert, Roland Marini Djang'Eing'A | 15 | - | - | ||||||||||||||||
| Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment - Philippe Hubert, Roland Marini Djang'Eing'A | ||||||||||||||||||||
| - | Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology - Philippe Hubert, Eric Ziemons | 5 | - | - | ||||||||||||||||
| Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology - Philippe Hubert, Eric Ziemons | ||||||||||||||||||||
| - | Statistical methods applied to the pharmaceutical industry - Bernadette Govaerts | 15 | - | - | ||||||||||||||||
| Statistical methods applied to the pharmaceutical industry - Bernadette Govaerts | ||||||||||||||||||||
| - | Experimental planning and "quality by design" - Bruno Boulanger | 10 | - | - | ||||||||||||||||
| Experimental planning and "quality by design" - Bruno Boulanger | ||||||||||||||||||||
| Regulation and the medical-social environment | 8 | |||||||||||||||||||
| Regulation and the medical-social environment | ||||||||||||||||||||
| - | Economic aspects of drug development - Dominique Martin | 10 | - | - | ||||||||||||||||
| Economic aspects of drug development - Dominique Martin | ||||||||||||||||||||
| - | Legislation and procedures applied to pharmaceutical industry, part a : legislation - Catherine Druez | 10 | 5 | - | ||||||||||||||||
| Legislation and procedures applied to pharmaceutical industry, part a : legislation - Catherine Druez | ||||||||||||||||||||
| - | Legislation and procedures applied to pharmaceutical industry, part b : patents and protection - Patrick Di Stefano | 5 | - | - | ||||||||||||||||
| Legislation and procedures applied to pharmaceutical industry, part b : patents and protection - Patrick Di Stefano | ||||||||||||||||||||
| - | Macroeconomic environment and pharmaco-economics - Pierre Duez | 10 | - | - | ||||||||||||||||
| Macroeconomic environment and pharmaco-economics - Pierre Duez | ||||||||||||||||||||
| - | CTD File (Common Technical Document) - Jean-Antoine De Muylder | 15 | - | - | ||||||||||||||||
| CTD File (Common Technical Document) - Jean-Antoine De Muylder | ||||||||||||||||||||
| - | Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files - Sonia Beken | 15 | - | - | ||||||||||||||||
| Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files - Sonia Beken | ||||||||||||||||||||
| - | Regulations of preclinical and clinical studies, part b : clinical studies - A Lenaers | 5 | - | - | ||||||||||||||||
| Regulations of preclinical and clinical studies, part b : clinical studies - A Lenaers | ||||||||||||||||||||
| - | Regulations of preclinical and clinical studies, part c : pediatric studies - Daniel Brasseur | 2,5 | - | - | ||||||||||||||||
| Regulations of preclinical and clinical studies, part c : pediatric studies - Daniel Brasseur | ||||||||||||||||||||
| - | Specific regulatory issues, part a : medicine and herbal dietary supplement - Michel Frederich | 5 | - | - | ||||||||||||||||
| Specific regulatory issues, part a : medicine and herbal dietary supplement - Michel Frederich | ||||||||||||||||||||
| - | Specific regulatory issues, part b : Preformulation and galenical development documentation - Francis Vanderbist | 5 | - | - | ||||||||||||||||
| Specific regulatory issues, part b : Preformulation and galenical development documentation - Francis Vanderbist | ||||||||||||||||||||
| Visits and seminars organised in the pharmaceutical industry - Françoise Dufrasne, Brigitte Evrard, Rita Van Bever - [77,5h Vis.] | - | - | [+] | 3 | ||||||||||||||||
| Visits and seminars organised in the pharmaceutical industry - Françoise Dufrasne, Brigitte Evrard, Rita Van Bever - [77,5h Vis.] | ||||||||||||||||||||
| Final work - Françoise Dufrasne, Brigitte Evrard, Rita Van Bever | - | - | - | 15 | ||||||||||||||||
| Final work - Françoise Dufrasne, Brigitte Evrard, Rita Van Bever | ||||||||||||||||||||